scholarly journals Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection

Hepatology ◽  
2014 ◽  
Vol 59 (6) ◽  
pp. 2083-2091 ◽  
Author(s):  
Hiromitsu Kumada ◽  
Yoshiyuki Suzuki ◽  
Kenji Ikeda ◽  
Joji Toyota ◽  
Yoshiyasu Karino ◽  
...  
Keyword(s):  
Hcv Genotype ◽  
Genotype 1B ◽  
Chronic Hcv

scholarly journals Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients

2017 ◽  
Vol 28 (2) ◽  
pp. 80-86 ◽  
Author(s):  
Daniel Palenzuela Gardón ◽  
Isabel Alicia Guillen ◽  
Julio R. Fernández ◽  
Hamlet Camacho ◽  
Zurina Cinza Estevez ◽  
...  
Keyword(s):  
Hcv Genotype ◽  
Genotype 1B ◽  
Chronic Hcv

Interferon-Free Regimen: Equally Effective in Treatment Naive and Experienced HCV Patients

2018 ◽  
Vol 17 (5) ◽  
pp. 0-10
Author(s):  
Crina Fofiu ◽  
Alina Boeriu ◽  
Felicia Coman ◽  
Alexandru Fofiu ◽  
Nikola Panic ◽  
...  
Keyword(s):  
Sustained Virologic Response ◽  
Virologic Response ◽  
High Rate ◽  
County Hospital ◽  
Treatment Experience ◽  
Hcv Genotype ◽  
Compensated Cirrhosis ◽  
Genotype 1B ◽  
Treatment Naïve ◽  
Chronic Hcv

Introduction and aim: Interferon-free regimen has been reported to be highly efficient in treatment of HCV infection, including patients with compensated cirrhosis. We compared the efficacy of Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir and Ribavirin (OBT/PTV/r, with DSV and RBV) therapy in patients with chronic HCV genotype 1b infection and compensated cirrhosis with and without prior treatment experience with pegylated interferon and ribavirin (IFN/RBV). Methods: A prospective two-center study was conducted in Mures County Hospital and Brasov County Hospital, Romania in period November 2015–July 2016. Both treatment naïve and PegIFN/RBV experienced patients with chronic HCV genotype 1b infection received 12 weeks of OBT/PTV/r, with DSV and RBV. Sustained virologic response 12 weeks after the treatment and eventual discontinuation of therapy due to adverse events were assessed in order to estimate safety and efficiency of therapeutic regimen. Results: Fifty nine patients were included in study, 35 (59.3%) of them were previously treated with IFN/RBV. Forty four (74.5%) patients were previously diagnosed with cirrhosis Child Pugh score 5, while 15 (25.4%) with Child Pugh score 6. All 59 patients achieved a SVR12 of 100% and one patient from treatment naïve cohort discontinued the therapy due to hyperbilirubinemia and encephalopathy. However viral load assessed at 12 weeks after discontinuation of therapy in this patient was undetectable. Conclusion: An all-oral regimen of co-formulated OBT/PTV/r with DSV and RBV results in high rate of sustained virologic response at post-treatment week 12 among HCV GT1b infected patients associated with compensated cirrhosis, regardless of previous treatment experience with PegIFN/RBV.

scholarly journals Daclatasvir Plus Asunaprevir Dual Therapy for Chronic HCV Genotype 1b Infection: Results of Turkish Early Access Program

2017 ◽  
Vol 16 (1) ◽  
pp. 71-76
Author(s):  
Seyfettin Köklü ◽  
Iftihar Köksal ◽  
Ulus Salih Akarca ◽  
Ayhan Balkan ◽  
Rahmet Güner ◽  
...  
Keyword(s):  
Dual Therapy ◽  
Hcv Genotype ◽  
Early Access ◽  
Genotype 1B ◽  
Chronic Hcv ◽  
Access Program
Sign in / Sign up

Export Citation Format

Share Document